Nasopharyngeal Carcinoma
Online Inquiry

Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma is one of the most common malignant tumors and the most common type of ear, nose, and throat cancer. Alfa Cytology is a world leader in the development of cancer vaccines. With our extensive experience and advanced platform, we are confident in providing the best vaccine development services for nasopharyngeal carcinoma.

Introduction to Nasopharyngeal Carcinoma

There are many risk factors for nasopharyngeal carcinoma, including genetic changes, viral infection, and environmental factors, among which the Epstein-Barr (EB) virus plays an important role in causing nasopharyngeal carcinoma. Nasopharyngeal cancer has a high degree of malignancy and is prone to metastasis.

There are many risk factors for nasopharyngeal carcinoma.Fig. 1 Hypothetical model of nasopharyngeal carcinoma pathogenesis. (Wong, K.C.W., et al., 2021)

The Difficulties of Nasopharyngeal Carcinoma Therapy

Because nasopharyngeal carcinoma is more sensitive to radiotherapy, radiotherapy combined with chemotherapy is the standard therapy for nasopharyngeal carcinoma. However, although the combination therapy regimen was superior to monotherapy in terms of overall survival and recurrence survival, the adverse effects of combination therapy were severe, especially the acute adverse effects.

Nasopharyngeal Carcinoma Vaccine

Tumor vaccine therapy is a tumor-specific active immunotherapy, which can be used as one of the immunotherapies for nasopharyngeal carcinoma. EB virus is highly associated with nasopharyngeal carcinoma and expresses viral proteins on the surface of tumor cells. Therefore, therapeutic cancer vaccines for nasopharyngeal carcinoma often target the EB virus antigen. Here are some other relevant specific targets.

  • Latent membrane proteins 1 (LMP1)
  • latent membrane proteins 2B (LMP2B)
  • BamHI-A rightward transcripts (BARTs)
  • Latent membrane proteins 2A (LMP2A)
  • EBV nuclear antigen 1 (EBNA1)
  • BamHI-A rightward frame 1 (BARF1)

Our Service

Nasopharyngeal carcinoma has a unique etiology and geographical distribution. It is a chemically sensitive disease with a 5-year survival rate of more than 80% for early disease. Although this disease is sensitive to chemotherapy, it inevitably develops resistance, and there is an urgent need for more effective immunotherapy. Against nasopharyngeal carcinoma, Alfa Cytology provides various services related to cancer vaccine development, including but not limited to the following.

Cancer vaccines have shown a broad and effective response in a variety of tumors, facilitating the development of immunotherapies for nasopharyngeal carcinoma. Alfa Cytology is committed to the research and development of therapeutic nasopharyngeal carcinoma vaccines, from the discovery of cancer antigens, and the development of different types of vaccines, to vaccine research for different cancer types, providing one-stop services. If you are interested in our service, please contact us.


  1. Wong, K.C.W., et al.; (2021) Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 18, 679–695.
 For Research Only.